Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer

Current Urology Reports

Volumn 14, Issue 2, 2013, Pages 65-70

  Barlow, Lamont J ^a   Benson, Mitchell C ^a  

^a Department of Medicine   (United States)

Author keywords

BCG; Bladder cancer; Docetaxel; Gemcitabine; Intravesical administration; Investigational therapies; Mitomycin; Paclitaxel; Taxanes; Treatment failure; Valrubicin

Indexed keywords

ABR 120052B; ANTINEOPLASTIC AGENT; BCG VACCINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; MITOMYCIN; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA; UNCLASSIFIED DRUG; VALRUBICIN;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; LOWER URINARY TRACT SYMPTOM; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DOXORUBICIN; HUMANS; MITOMYCIN; PACLITAXEL; TAXOIDS; THIOTEPA; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 84879607172     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0312-2     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Rubben H, Lutzeyer W, Fischer N, et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 1988;139:283-5.
3. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180-3.
4. Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol. 1982;128:1104-8.
5. Nadler R, Luo Y, Zhao W, et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol. 2003;131:206-16.
6. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137:155-8.
7. Ratliff TL, Ritchey JK, Yuan JJ, et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150:1018-23.
8. Mungan NA, Witjes JA. Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol. 1998;82:213-23.
9. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964-9.
10. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin- induced antitumor activity. Cancer Res. 2004;64:3386-90.
11. Jones J, Campbell S. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Wein A, Kavoussi L, Novick A, Partin A, Peters C, editors. Campbell-Walsh urology, 9 edn, vol. 3. Philadelphia: Saunders; 2006. p. 2447-67.
12. Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol. 1996;156:962-6.
13. Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol. 1984;132:457-9.
14. Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987;137:220-4.
15. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23:675-80.
16. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169:1706-8.
17. Lambert EH, Pierorazio PM, Olsson CA, et al. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100:33-6.
18. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181:1040-5.
19. Malmstrom PU, Wijkstrom H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161:1124-7.
20. Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2009;28:543-8.
21. Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52:1123-9.
22. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology. 1997;49:471-5.
23. Patterson AL, Greenberg RE, Weems L, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2000;56:232-5.
24. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163:761-7.
25. • Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol 2012, doi: 10.1016/j.urolonc.2012.04.010. The authors report the long-term recurrence data from a combined phase II/III trial of intravesical valrubicin.
26. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol. 1985;57:680-85.
27. Heney NM. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa. Urology. 1985;26:27-9.
28. Heney NM, Koontz WW, Barton B, et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol. 1988;140:1390-3.
29. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin N Am. 1992;19:529-39.
30. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005;66:726-31.
31. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729-34.
32. Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology. 2005;65:65-9.
33. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20:3193-8.
34. Grossman HB, O'Donnell MA, Cookson MS, et al. Bacillus calmette-guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol. 2008;10:281-9.
35. •• Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1:CD009294. This is a comprehensive review of randomized controlled trials of intravesical gemcitabine. It includes 704 patients from six studies.
36. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-5.
37. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-8.
38. Perdona S, Di Lorenzo G, Cantiello F, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21:101-6.
39. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. 2012 American Urological Association Annual Meeting; 2012. May 22nd; Atlanta, Georgia, 2012.
40. Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol. 2002;20:158-66.
41. Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol. 1997;40:285-92.
42. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24:3075-80.
43. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2009;75:134-7.
44. Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. BJU Int. 2009;104:1098-102.
45. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel in the management of non-muscle-invasive bladder cancer (NMIBC) refractory to BCG therapy. 2012 American Urological Association Annual Meeting; 2012. May 22nd; Atlanta, Georgia, 2012.
46. • Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with Intravesical Docetaxel in the management of recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette-Guerin therapy. J Urol. 2012, doi: 10.1016/j.juro.2012.10.068. This is the largest published series of intravesical docetaxel. It includes long-term recurrence and survival outcomes as well as the impact of maintenance docetaxel on delaying recurrence.
47. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166:1296-9.
48. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136-43.
49. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-803.
50. McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186:448-51.